News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 181–216
- Matches
- 837
- Sources here
- 23
- Companies here
- 15
Active search
837 matching headlines
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Crake Asset Management boosts Alphabet Class C stake by 411,000 shares
Crake Asset Management LLP, led by Richard Walker, has significantly increased its holdings in Alphabet Inc. Class C (GOOG) by acquiring an additional 411,000 shares. TipRanks' AI Analyst, Spark, rates GOOG as "Outperform" due to strong financial performance, a positive earnings outlook driven by …
Damora Therapeutics, Inc. SEC Filing (Aug 10, 2026)
Damora Therapeutics, Inc. (DMRA) filed a post-effective amendment to its S-3 registration statement on August 10, 2026. This amendment follows the company's redomestication from Delaware to the Cayman Islands on July 16, 2026, and clarifies that no new securities are being registered. The filing …
Damora Therapeutics Q2 Results: Net Loss Widens To $31.2 Million
Damora Therapeutics reported a net loss of $31.2 million for Q2 2026, a significant increase from $3.4 million in the prior year, primarily due to soaring R&D expenses for its CLARITY-101 trial. Despite the widening loss, the company boasts strong liquidity with $540.5 million …
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) announced its quarterly earnings, reporting a loss of $0.39 per share, which surpassed analysts' consensus estimate of a $0.45 loss by $0.06. Following the announcement, shares fell 1.3% to $29.54, resulting in a market capitalization of approximately $1.82 …
Damora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
Damora Therapeutics, Inc. announced its financial results for the second quarter and first six months of 2026, ending June 30th. The company reported a significant increase in net loss for both periods compared to the previous year. For the second quarter, the net loss …
Wall Street Divided on Diamondback Energy as Jefferies and Bernstein Issue Diverging Price Target Revisions
Wall Street analysts are showing mixed signals on Diamondback Energy (FANG), with Jefferies raising its price target to $205 while maintaining a Hold rating, and Bernstein lowering its target to $221 but keeping an Outperform rating. Despite these differing revisions, the overall analyst consensus, …
Diamondback Energy On Pace for Largest Percent Increase Since April 2025 -- Data Talk
Diamondback Energy, Inc. (FANG) is experiencing a significant surge, currently up 5.35% at $198.10, putting it on track for its largest percentage increase since April 2025. This performance makes it the ninth best performer in the S&P 500 and fourth best in the Nasdaq …
Diamondback Energy (NASDAQ:FANG) Given New $220.00 Price Target at Citigroup
Citigroup has adjusted its price target for Diamondback Energy (NASDAQ:FANG) to $220.00, a slight decrease from $221.00, while maintaining a "buy" rating. This new target suggests a potential upside of 12.58% from the stock's last close. The company recently surpassed quarterly earnings and revenue …
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026
Damora Therapeutics, Inc. Common Stock (DMRA) reported Q2 2026 earnings on August 10, 2026, with an EPS of -$0.39, beating the consensus estimate of -$0.45. The company's earnings are projected to decrease in the next year, from ($2.06) to ($2.14) per share. The article …
Did Sylvamo’s (SLVM) Quarterly Loss Subtly Reshape Its Long-Term Earnings Story?
Sylvamo Corporation reported a Q2 2026 net loss of US$11 million and a first-half loss of US$14 million, reversing its net income from the previous year, despite slightly higher sales. This raises questions about margin recovery and free cash flow, especially given significant capital …
Diamondback Energy’s new Midland Basin wells’ results are rising, not sputtering out. SM Energy’s Midland results are overcoming the E&P’s “science-heavy” spell.
The article highlights that Diamondback Energy and SM Energy are demonstrating sustained and improving well productivity in the Midland Basin, defying expectations of degradation. Despite a decrease in active rig counts, Permian tight oil and shale production remain robust due to efficiency gains, longer …
Renaissance Technologies LLC Purchases 14,000 Shares of Alamo Group, Inc. $ALG
Renaissance Technologies LLC significantly increased its stake in Alamo Group, Inc. (NYSE:ALG) during the first quarter, adding 14,000 shares to bring its total holding to 16,400 shares, valued at approximately $2.7 million. The company reported strong quarterly earnings, surpassing analyst expectations with $2.82 in …
Does CLARITY-101’s mutCALR Antibody Launch Change The Bull Case For Damora Therapeutics (DMRA)?
Damora Therapeutics (DMRA) has initiated its Phase 1/1b CLARITY-101 trial for DMR-001, a first-in-class antibody targeting mutant calreticulin in myelofibrosis and essential thrombocythemia. This trial launch de-risks execution and provides a clear catalyst with mid-2027 data, though risks remain due to the company's early-stage, …
Diamondback Energy Inc Stock Price Live, Charts & News - The Economic Times
This article provides a live overview of Diamondback Energy Inc. (FANG) stock, including its current price, daily performance, and key financial metrics. It details the company's market capitalization, P/E ratio, dividend yield, and historical returns, along with quarterly balance sheets, income statements, and cash …
Nathan's Famous (NATH) Stock Revenue Strength Meets Margin And Debt Questions
Nathan's Famous (NATH) reported strong Q1 2027 revenue of US$54.1m, a significant increase from the previous year, but net income and EPS slightly declined, and store count marginally decreased. While the company's brand strength continues to drive revenue, concerns are rising regarding thinning margins …
(CPZ) and the Role of Price-Sensitive Allocations
This article analyzes Calamos Long/short Equity & Dynamic Income Trust (NYSE: CPZ) using AI models to generate trading strategies. It highlights strong near and mid-term sentiment, weak long-term outlook, and compelling upside potential due to no remaining resistance levels above the current price. The …
Nathan's Famous reports Q1 revenues $54.06M, adjusted EBITDA $13.62M
Nathan's Famous (NATH) reported its first-quarter fiscal 2027 results, showing revenues of $54.06 million and adjusted EBITDA of $13.62 million. The company's net income was $8.83 million, or $2.14 diluted EPS. Product licensing, including royalties from Smithfield Foods, significantly increased, while a rise in …
NATH Stock Alert: Halper Sadeh LLC is Investigating Whether Nathan’s Famous, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Nathan’s Famous, Inc. (NATH) to Smithfield Foods, Inc. for $102.00 per share. The investigation will examine whether Nathan’s board violated federal securities laws or breached fiduciary duties by not securing the …
Does Alamo Group’s (ALG) Buybacks and Bylaw Changes Reveal a Deeper Shift in Governance Priorities?
Alamo Group Inc. recently reported its Q2 2026 results, showing increased sales but slightly lower net income, alongside a completed share repurchase program. Concurrently, the company updated its bylaws to tighten shareholder proposal and director nomination procedures, formalize director compensation, and address conflicts of …